GOALS OF WORK: The aims of this study were (1) to evaluate quality of life (QoL), nutritional status and dietary intake taking into account the stage of disease and therapeutic interventions, (2) to determine potential interrelationships, and (3) to quantify the relative contributions of the cancer, nutrition and treatments on QoL. PATIENTS AND METHODS: In this prospective cross-sectional study conducted in 271 head and neck, oesophagus, stomach and colorectal cancer patients, the following aspects were evaluated: QoL (EORTC-QLQ C30), nutritional status (percent weight loss over the previous 6 months), usual diet (comprehensive diet history), current diet (24-h recall) and a range of clinical variables. MAIN RESULTS: Usual and current intakes differed according to the site of the tumour ( P=0.02). Patients with stage III/IV disease showed a significant reduction from their usual energy/protein intake ( P=0.001), while their current intakes were lower than in patients with stage I/II disease ( P=0.0002). Weight loss was greater in patients with stage III/IV disease than in those with stage I/II disease ( P=0.001). Estimates of effect size revealed that QoL function scores were determined in 30% by cancer location, in 20% by nutritional intake, in 30% by weight loss, in 10% by chemotherapy, in 6% by surgery, in 3% by disease duration and in 1% by stage of disease. Likewise in the case of symptom scales, 41% were attributed to cancer location, 22% to stage, 7% to nutritional intake, 7% to disease duration, 4% to surgery, 1% to weight loss and 0.01% to chemotherapy. Finally for single items, 30% were determined by stage, 20% by cancer location, 9% by intake, 4% by surgery, 3% by weight loss, 3% by disease duration and 1% by chemotherapy. CONCLUSIONS: Although cancer stage was the major determinant of patients' QoL globally, there were some diagnoses for which the impact of nutritional deterioration combined with deficiencies in nutritional intake may be more important than the stage of the disease process.
GOALS OF WORK: The aims of this study were (1) to evaluate quality of life (QoL), nutritional status and dietary intake taking into account the stage of disease and therapeutic interventions, (2) to determine potential interrelationships, and (3) to quantify the relative contributions of the cancer, nutrition and treatments on QoL. PATIENTS AND METHODS: In this prospective cross-sectional study conducted in 271 head and neck, oesophagus, stomach and colorectal cancerpatients, the following aspects were evaluated: QoL (EORTC-QLQ C30), nutritional status (percent weight loss over the previous 6 months), usual diet (comprehensive diet history), current diet (24-h recall) and a range of clinical variables. MAIN RESULTS: Usual and current intakes differed according to the site of the tumour ( P=0.02). Patients with stage III/IV disease showed a significant reduction from their usual energy/protein intake ( P=0.001), while their current intakes were lower than in patients with stage I/II disease ( P=0.0002). Weight loss was greater in patients with stage III/IV disease than in those with stage I/II disease ( P=0.001). Estimates of effect size revealed that QoL function scores were determined in 30% by cancer location, in 20% by nutritional intake, in 30% by weight loss, in 10% by chemotherapy, in 6% by surgery, in 3% by disease duration and in 1% by stage of disease. Likewise in the case of symptom scales, 41% were attributed to cancer location, 22% to stage, 7% to nutritional intake, 7% to disease duration, 4% to surgery, 1% to weight loss and 0.01% to chemotherapy. Finally for single items, 30% were determined by stage, 20% by cancer location, 9% by intake, 4% by surgery, 3% by weight loss, 3% by disease duration and 1% by chemotherapy. CONCLUSIONS: Although cancer stage was the major determinant of patients' QoL globally, there were some diagnoses for which the impact of nutritional deterioration combined with deficiencies in nutritional intake may be more important than the stage of the disease process.
Authors: A de Graeff; R J de Leeuw; W J Ros; G J Hordijk; J J Battermann; G H Blijham; J A Winnubst Journal: Head Neck Date: 1999-07 Impact factor: 3.147
Authors: F Bozzetti; S Migliavacca; A Scotti; M G Bonalumi; D Scarpa; F Baticci; M Ammatuna; A Pupa; G Terno; C Sequeira; C Masserini; H Emanuelli Journal: Ann Surg Date: 1982-08 Impact factor: 12.969
Authors: O E Owen; E Kavle; R S Owen; M Polansky; S Caprio; M A Mozzoli; Z V Kendrick; M C Bushman; G Boden Journal: Am J Clin Nutr Date: 1986-07 Impact factor: 7.045
Authors: C Roberge; M Tran; C Massoud; B Poirée; N Duval; E Damecour; D Frout; D Malvy; F Joly; P Lebailly; M Henry-Amar Journal: Br J Cancer Date: 2000-01 Impact factor: 7.640
Authors: Gefter Thiago Batista Corrêa; Gabriela Alencar Bandeira; Bruna Gonçalves Cavalcanti; Francis Balduíno Guimarães Santos; João Felício Rodrigues Rodrigues Neto; André Luiz Sena Guimarães; Desirée Sant'Ana Haikal; Alfredo Maurício Batista De Paula Journal: Support Care Cancer Date: 2012-11 Impact factor: 3.603
Authors: Giorgio Capuano; Pier Carlo Gentile; Federico Bianciardi; Michela Tosti; Anna Palladino; Mario Di Palma Journal: Support Care Cancer Date: 2009-06-29 Impact factor: 3.603
Authors: S Culine; C Chambrier; A Tadmouri; P Senesse; P Seys; A Radji; M Rotarski; A Balian; P Dufour Journal: Support Care Cancer Date: 2014-02-21 Impact factor: 3.603
Authors: Thomas R Palser; David A Cromwell; Richard H Hardwick; Stuart A Riley; Kimberley Greenaway; William Allum; Jan Hp van der Meulen Journal: BMC Health Serv Res Date: 2009-11-12 Impact factor: 2.655